Commission Implementing Regulation (EU) 2026/351 of 18 February 2026 renewing the approval of the active substance spinosad in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) No 540/2011
Proposed act with possible EEA relevance
Act under scrutiny by EEA EFTA
Draft Joint Committee Decision (JCD) under consideration
Entry into force of Joint Committee Decision (JCD) pending
Incorporated into the EEA Agreement and in force
Incorporated into the EEA Agreement but no longer in force
Legal status
EU legal act incorporated into the EEA Agreement by a Joint Committee Decision (JCD)
Area (EEA Agreement)
II Technical Regulations, Standards, Testing and Certification
II.XV Dangerous Substances
Joint committee decision (JCD)
171/2026
In force in the EEA
Yes
Legal Documents
Commission Implementing Regulation (EU) 2026/351 of 18 February 2026 renewing the approval of the active substance spinosad in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) No 540/2011
Framkvæmdarreglugerð framkvæmdastjórnarinnar (ESB) 2026/351 frá 18. febrúar 2026 um endurnýjun á samþykki fyrir virka efninu spínósaði, í samræmi við reglugerð Evrópuþingsins og ráðsins (EB) nr. 1107/2009, og um breytingu á framkvæmdarreglugerð framkvæmdastjórnarinnar (ESB) nr. 540/2011
Durchführungsverordnung (EU) 2026/351 der Kommission vom 18. Februar 2026 zur Erneuerung der Genehmigung für den Wirkstoff Spinosad gemäß der Verordnung (EG) Nr. 1107/2009 des Europäischen Parlaments und des Rates sowie zur Änderung der Durchführungsverordnung (EU) Nr. 540/2011 der Kommission
History
Disclaimer: EEA-Lex is provided for information purposes only. The information is not guaranteed or promised to be current or complete and is not intended to replace any applicable legal sources.